Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Brought to you by

Mesoblast partners stem cell drugs exclusively with Cephalon

14 Jun 2016

Executive Summary

Australian regenerative medicine firm Mesoblast Ltd. has licensed Cephalon Inc. exclusive global rights to therapeutics derived from adult mesenchymal precursor stem cells (MPCs) for degenerative neurological and cardiovascular diseases including congestive heart failure, acute myocardial infarction, angina, peripheral vascular disease/critical limb ischemia, Parkinson's, stroke, multiple sclerosis, Huntington's, and Alzheimer's. The deal will also include cell products that expand hematopoietic stem cell (bone marrow) transplants for blood cancer patients.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By